These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28263395)

  • 1. Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints.
    Beisel C; Benner A; Kunz C; Kopp-Schneider A
    Biom J; 2017 May; 59(3):511-530. PubMed ID: 28263395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing small sample size bias in multiple-biomarker trials: Inclusion of biomarker-negative patients and Firth correction.
    Habermehl C; Benner A; Kopp-Schneider A
    Biom J; 2018 Mar; 60(2):275-287. PubMed ID: 28762532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample-size calculation and reestimation for a semiparametric analysis of recurrent event data taking robust standard errors into account.
    Ingel K; Jahn-Eimermacher A
    Biom J; 2014 Jul; 56(4):631-48. PubMed ID: 24817598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sample size formula for the supremum log-rank statistic.
    Eng KH; Kosorok MR
    Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size.
    Xu R; Mehrotra DV; Shaw PA
    Pharm Stat; 2019 May; 18(3):366-376. PubMed ID: 30706642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust covariate-adjusted log-rank statistics and corresponding sample size formula for recurrent events data.
    Song R; Kosorok MR; Cai J
    Biometrics; 2008 Sep; 64(3):741-750. PubMed ID: 18162107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.
    Abel UR; Jensen K; Karapanagiotou-Schenkel I; Kieser M
    J Biopharm Stat; 2015; 25(6):1285-311. PubMed ID: 25629760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
    Phadnis MA; Wetmore JB; Mayo MS
    Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect.
    Ye T; Yu M
    Biometrics; 2018 Dec; 74(4):1292-1300. PubMed ID: 29992543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stratified Fisher's exact test and its sample size calculation.
    Jung SH
    Biom J; 2014 Jan; 56(1):129-40. PubMed ID: 24395208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An efficient alternative to the stratified Cox model analysis.
    Mehrotra DV; Su SC; Li X
    Stat Med; 2012 Jul; 31(17):1849-56. PubMed ID: 22437375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata.
    Lachin JM
    Stat Med; 2013 Nov; 32(25):4413-25. PubMed ID: 23670965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size determination for comparing more than two survival distributions.
    Ahnn S; Anderson SJ
    Stat Med; 1995 Oct; 14(20):2273-82. PubMed ID: 8552903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size in cluster-randomized trials with time to event as the primary endpoint.
    Jahn-Eimermacher A; Ingel K; Schneider A
    Stat Med; 2013 Feb; 32(5):739-51. PubMed ID: 22865817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions.
    Phadnis MA; Mayo MS
    Biom J; 2021 Oct; 63(7):1406-1433. PubMed ID: 34272897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size considerations for the evaluation of prognostic factors in survival analysis.
    Schmoor C; Sauerbrei W; Schumacher M
    Stat Med; 2000 Feb; 19(4):441-52. PubMed ID: 10694729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size computation for two-sample noninferiority log-rank test.
    Jung SH; Kang SJ; McCall LM; Blumenstein B
    J Biopharm Stat; 2005; 15(6):969-79. PubMed ID: 16279355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size estimation for cancer randomized trials in the presence of heterogeneous populations.
    Dinart D; Bellera C; Rondeau V
    Biometrics; 2022 Dec; 78(4):1662-1673. PubMed ID: 34242412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An online updating approach for testing the proportional hazards assumption with streams of survival data.
    Xue Y; Wang H; Yan J; Schifano ED
    Biometrics; 2020 Mar; 76(1):171-182. PubMed ID: 31424095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.